Vaxcyte COO Exercises Deeply Discounted Options in $378,000 Insider Sale

Jim Wassil, Chief Operating Officer of Vaxcyte, Inc. (NASDAQ:PCVX), recently executed a significant insider transaction. According to an SEC Form 4 filing, Wassil sold 6,182 shares of common stock on August 31 and September 1, totaling approximately $378,000.

Key Points

• The transaction represented a combined value of roughly $378,000, based on a weighted average price of $61.12 per share.
• The sale accounted for approximately 4% of Wassil’s previously held stake.
• The disposition included 2,705 shares withheld to cover tax obligations, alongside the exercise and immediate sale of 2,250 options under a Rule 10b5-1 trading plan.

Transaction Summary

Transaction value based on SEC Form 4 weighted average sale price ($61.12); post-transaction value based on the September 2 market close ($61.58).

Key Questions

• What was the impact of the derivative transactions?
  Wassil exercised 2,250 options at an exercise price of $5.35 per share—a significant discount to the weighted average execution price of $61.12. These shares were immediately sold as part of the overall disposition.
• How much of the trading volume was non-discretionary?
  A portion of the activity involved 2,705 shares surrendered to the company to satisfy tax withholding obligations triggered by the vesting of restricted stock units. The remaining open-market sales were executed under a Rule 10b5-1 trading plan adopted on December 9, 2025.
• What is the current status of the insider’s equity position?
  Following these transactions, Jim Wassil maintains direct ownership of 153,609 shares of common stock, representing a 0.11% ownership interest in the company. He also holds 66,648 derivative securities.
• How does the current stock price compare to the transaction level?
  Vaxcyte shares closed at $60.81 on September 1, which is 0.51% below the weighted average price of $61.12 achieved during the reported transactions.

Company Overview

Company Snapshot

• Vaxcyte is a clinical-stage biotechnology company dedicated to developing innovative protein-based vaccines to prevent and manage bacterial infectious diseases. Its lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine currently undergoing Phase 1/2 clinical trials.
• The company operates a development-stage business model focused on advancing proprietary vaccine candidates through clinical trials, with the ultimate goal of commercialization and licensing partnerships with established pharmaceutical entities.
• Vaxcyte’s primary target markets encompass healthcare systems, public health agencies, and pharmaceutical partners seeking next-generation vaccines to address unmet medical needs in infectious disease prevention, particularly among immunocompromised and elderly populations.

Vaxcyte, Inc. is a clinical-stage biotechnology enterprise headquartered in San Carlos with 507 employees. The company focuses on developing next-generation protein-based vaccines to address significant gaps in infectious disease prevention. Leveraging advanced conjugate vaccine technology, Vaxcyte creates multi-valent formulations with enhanced immunogenicity and broader pathogen coverage compared to existing therapeutic options. With a market capitalization of $9.0 billion and a 95% share price appreciation over the past year, Vaxcyte reflects strong investor confidence in its clinical pipeline and the substantial market opportunity within the global vaccine sector.

What This Transaction Means for Investors

Wassil exercised 2,250 options struck at $5.35 and sold the shares alongside the rest of his disposition, which stems from a grant predating much of Vaxcyte’s current valuation. The open-market portion was scheduled under a plan adopted on December 9, 2025, while 2,705 shares were withheld for taxes on vesting stock. Following the transactions, Wassil retains 153,609 shares and 66,648 exercisable options.

As Chief Operating Officer, Wassil oversees the construction of the manufacturing base for a vaccine not yet approved. Research and development spending surged to $267.9 million in the second quarter, up from $194.2 million a year earlier, with the company attributing the increase partly to manufacturing activities supporting potential future commercial launches. Vaxcyte must also complete a lot-to-lot consistency study—the trial demonstrating batch-to-batch uniformity—which serves as the final Phase 3 requirement before an FDA filing. The company must wait to submit for approval until this study concludes and the OPUS-2 and OPUS-3 results are released in the first half of 2027.

Source link